Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 10/20 | 0.35 |
| ▸ | TK2 | O00142 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558374 | 0.84 | DRD2 (0.41) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL3564835 | 0.81 | DRD2 (0.44) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL1484499 | 0.81 | DRD2 (0.42) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL2559163 | 0.77 | KDM4E (0.50) | LMNASMN1; SMN2TK1GRIA1GRIA2 | |
| SCHEMBL23873406 | 0.75 | GRIA1 (0.42) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL8768989 | 0.75 | KMT2A (0.43) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL13314160 | 0.74 | CYP1A2 (0.50) | LMNASMN1; SMN2DRD2DRD3TK1 | |
| SCHEMBL3561793 | 0.74 | DRD2 (0.46) | LMNAALOX12ADRA1ASMN1; SMN2DRD2 | |
| SCHEMBL6714052 | 0.74 | TK1 (0.57) | TK1TK2 | |
| SCHEMBL31087986 | 0.74 | CYP1A2 (0.50) | TK1GRIA1GRIA2GRIA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| WO-2021191830-A1 | METHODS AND REAGENTS FOR SYNTHESIZING NUCLEOSIDES AND ANALOGUES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | NUDT1, ADAR, APRT | LMNA 1420/4885ALOX12 2938/4885ADRA1A 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.